<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802996</url>
  </required_header>
  <id_info>
    <org_study_id>MAGIC-301</org_study_id>
    <nct_id>NCT01802996</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury</brief_title>
  <acronym>MAGIC</acronym>
  <official_title>A Randomized, Controlled, Multi-center Collaborative Study to Evaluate the Efficacy of Magnesium Isoglycyrrhizinate Injection in the Prevention of Antineoplastic Chemotherapy Related Acute Liver Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cttq</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to evaluate the evaluate the efficacy of Magnesium
      Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute
      liver injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total subjects: 2040, experimental group of 1360 patients, control group of 680 patients.
      According to the study subjects receiving antineoplastic chemotherapy, subjects are
      stratified randomize.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of liver injury</measure>
    <time_frame>0-15 days</time_frame>
    <description>anyone of ALT、AST、ALP、TBIL、DBIL、γ-GT＞ULN</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2040</enrollment>
  <condition>Neoplasms</condition>
  <condition>Liver Injury</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Isoglycyrrhizinate Injection</intervention_name>
    <description>200mg IV on day 1-5</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Tianqingganmei®</other_name>
    <other_name>2005S07127</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 18-75 years;

          2. Patients with malignant tumor accord with chemotherapy indication, candidate to a
             chemotherapy treatment, disease is not restricted;

          3. Accorded with the following chemotherapy plan: included cis-platinum, ≥60mg/m2/course;
             included oxaliplatin, ≥85mg/m2/course; included cyclophosphamide, ≥600mg/m2/course;
             included gemcitabine, ≥60mg/m2/course;

          4. ECOG≤2;

          5. Estimates survival time≥3 months;

          6. TBIL≤1.0×ULN, ALT、AST≤1.0×ULN; blood examination, uronoscopy, stool examination, renal
             function tests and electrocardiogram are normal;

          7. Patients have been apart from the previous chemotherapy to finish above 2 weeks
             (including 2 weeks).

        Exclusion Criteria:

          1. Patients with partial liver radiotherapy;

          2. Hepatitis B or C virus replication in the state, the patient will need antiviral
             therapy;

          3. Patients have serious heart diseases, liver kidney diseases, or metabolism function
             disorder;

          4. Patients combined with cellular immune therapy;

          5. Within 2 weeks of application or currently possible applications of drugs(polyene
             phosphatidylcholine, reduced glutathione, tiopronin and other hepatoprotective and
             choleretic drugs), interference with the study;

          6. Pregnancy, or patients during breast feeding;

          7. Patients have known hypersensitivity to Glycyrrhizin;

          8. Patients are participating, or have participated in other Clinical studies of new
             drugs within 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qin Shukui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 81st hospital of PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua haiqing, MD</last_name>
    <phone>0086-025-80864049</phone>
    <email>huahaiqing@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Jinhua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Lijie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of General Hospital of PLA ( 304 )</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Junxun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Province-owned Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Zhenhe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Military Area Command</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Xi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Dengyun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ouyang Ming</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tumour Hospital Affiliated to Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Wensheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yongqiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lan Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>An Yonghui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xie Shaojian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The people's Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Yi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong Meizuo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzhou Second People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Keqin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 81st hospital of PLA</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Haiqing, MD</last_name>
      <phone>0086-025-80864049</phone>
      <email>huahaiqing@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Qin Shukui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital of Nanjing Military Area Command</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Rui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Lingjun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Jinfei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Keming</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi Fourth People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Chaoying</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Haiyang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiong Jianping</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Medical College of Qiingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiu Wensheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Hua</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2013</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

